X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Clover gains commercial rights to AdimFlu-S (quadrivalent influenza vaccine) in mainland China, Bangladesh, Brazil and the Philippines. AdimFlu-S is a quadrivalent split inactivated vaccine intended for use in the prevention of influenza.
Lead Product(s): Quadrivalent Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: AdimFlu-S
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Clover Biopharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 19, 2023
Details:
Under the terms of the Master Service Agreement, JHL Biotech will support Adimmune Corporation to manufacture and supply the Antigen for their leading Covid-19 vaccine candidate.
Lead Product(s): Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Recipient: Eden Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 11, 2020
Details:
Adimmune had designed and produced 4 prototypes of antigens to fight Covid-19 based on its recombinant protein technology, and has tested one prototype in a BSL-3 lab at National Taiwan University.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
